<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116413</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2013/CR-01</org_study_id>
    <secondary_id>2013-A01702-43</secondary_id>
    <nct_id>NCT02116413</nct_id>
  </id_info>
  <brief_title>Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?</brief_title>
  <acronym>FC-Rev</acronym>
  <official_title>Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate in a population of patients with septic
      shock receiving 500 ml crystalloid over 10 minutes, the proportion of patients classified as
      &quot;responders&quot; to the fluid challenge (increase of at least 15% of ITV in aortic) at the end
      of vascular filling (T10) and becoming &quot;non-responders&quot; 20 minutes after the end of the
      fluid challenge (T30) and whether this proportion is greater than 10 points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are :

      A. To assess changes in different ultrasound parameters: E wave , E / A ratio , E / E ' in
      the event of vascular filling and construct a dose response curve for vascular filling.

      B. To determing a threshold value for the mitral E wave velcoity that can predict a positive
      response to volume expansion at T10 defined by a 15% increase in the sub aortic velocity
      time integral (ITV) after 500 ml of crystalloids in 10 minutes.

      C. To determine a threshold value for theITV at T0 that can predict a positive response to
      volume expansion at T10 defined by a 15% increase in the ITV after 500 ml of crystalloids in
      10 minutes.

      D. To evaluate the proportion of responders at T10 becoming non-responders at T20.

      E. To evaluate the proportion of nonresponders at T10 and responders at T30 .

      F. To estimate the proportion of patients changing status regardless of the direction of
      change between T10 and T30 .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Patient status changes from &quot;responder&quot; at the end of the fluid challenge (T10) to &quot;non-responder&quot; 20 minutes after the end of the fluid challenge (T30).</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>Baseline (minute 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>4 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>6 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>8 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral E wave</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>Baseline (minute 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>4 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>6 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>8 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral A wave</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>Baseline (minute 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>4 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>6 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>8 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E' Wave at the lateral mitral annulus</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITV</measure>
    <time_frame>Baseline (minute 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITV</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITV</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITV</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient status changes from &quot;responder&quot; at the end of the fluid challenge (T10) to &quot;non-responder&quot; 10 minutes after the end of the fluid challenge (T20).</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient status changes from &quot;non-responder&quot; at the end of the fluid challenge (T10) to &quot;responder&quot; 20 minutes after the end of the fluid challenge (T30).</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>The study population</arm_group_label>
    <description>The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:
oliguria &lt;0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate &gt; 2 mmol / l SvcO2 &lt;70% or SvO2 &lt;65% Patient on noradrenaline.
Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate&gt; 4 mmol / l or organ dysfunction.
Intervention:  Fluid challenge Intervention: Cardiac ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluid challenge</intervention_name>
    <description>The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.</description>
    <arm_group_label>The study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac ultrasound</intervention_name>
    <description>Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.</description>
    <arm_group_label>The study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients admitted to intensive care, sedated and under
        controlled ventilatory support with septic shock criteria defined by severe sepsis
        associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring
        vascular filling according to the following criteria:

          -  oliguria &lt;0.5 ml / kg / h for at least 2h

          -  skin mottling

          -  Arterial Lactate &gt; 2 mmol / l

          -  SvcO2 &lt;70% or SvO2 &lt;65%

          -  Patient on noradrenaline.

        Severe sepsis is defined as a systemic inflammatory response associated with a suspected
        or proven infection and hypotension before filling, a lactate&gt; 4 mmol / l or organ
        dysfunction.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has given his/hers consent or the patient is in an emergency situation
             (commitment to obtain the consent of the patient as soon as his/her condition
             permits)

          -  Patient affiliated or beneficiary of a health insurance plan

          -  Patient with septic shock: proven or suspected infection associated with hypotension
             or lactate&gt; 4 mmol / l or organ dysfunction. Hypotension despite fluid resuscitation
             of 20 to -40 ml / kg.

          -  Patient under controlled mechanical ventilation

          -  Patient requiring vascular filling according to the following criteria:

          -  oliguria &lt;0.5 ml / kg / h for at least 2h

          -  skin mottling

          -  Arterial Lactate &gt; 2 mmol / l

          -  SvcO2 &lt;70% or SvO2 &lt;65%

          -  Patient on noradrenaline.

        Exclusion Criteria:

          -  The patient is has in another interventional study that might change the results of
             this study within the past 3 months

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  The patient is pregnant, parturient, or breastfeeding

          -  Valvular pathology: grade III and IV aortic or mitral insufficiency

          -  Non sinus electrocardiogram

          -  Non-echogenic patient

          -  Patient with any spontaneous breathing

          -  Moribund patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Roger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Roger, MD</last_name>
    <phone>+33.(0)4.66.68.30.50</phone>
    <email>claire.roger@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey M Suehs, PhD</last_name>
    <phone>+33.0()4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hervé Dupont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yazine Mahjoub, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gaël Piton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Luc Fellahi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Masson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Hôpital Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Michel Constantin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Hôpital Gabriel-Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Russell Chabanne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Sebastien Faure, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Leone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît Ragonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Lakal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital St-Roch</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Caroline Ichai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey Scarlatti-Rendard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé Quintard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire Roger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Yves Lefrant, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Jeannes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Louart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Louart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Boutin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saber Barbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffroy Dingemans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Bengler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Barbaste, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Muller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluid challenge</keyword>
  <keyword>fluid resuscitation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
